Suicidality

This report summarises what Blossom’s database shows about psychedelic and rapid-acting treatments for suicidality, and, just as importantly, what it does not show. The short version: the strongest evidence is that ketamine and esketamine can reduce suicidal thoughts quickly, and esketamine has a regulatory approval that names suicidality. But reducing ideation in a trial is not the same as preventing suicide, the people at highest risk are usually excluded from the studies, and classic psychedelics remain unproven and carry real risks for people in crisis. Caution, not enthusiasm, is the honest posture here.

If you are in crisis, read this first

If you are having thoughts of suicide, please reach out for help now. Contact your local emergency services, or a crisis line: in the US you can call or text 988 (the Suicide and Crisis Lifeline); in the UK and Ireland you can call Samaritans on 116 123; and findahelpline.com lists free, confidential services in most countries. You are not alone, and help is available. Nothing on this page is a treatment recommendation, and none of the compounds discussed should be used for a suicidal crisis outside professional medical care.

A note before the evidence

This page is a research summary, not medical advice, and nothing here is a treatment recommendation. Of the treatments discussed, only ketamine (off-label) and esketamine are in routine clinical use, and both are given under medical supervision; the classic psychedelics are investigational. Decisions about treating depression and suicide risk belong with a qualified clinician.

On the numbers: Blossom currently tracks 246 papers and 94 trials tagged to this topic, and those counts appear on this page. The tag is leaky. A large share of the records are about depression broadly, or carry suicidality only as a secondary or safety outcome, including studies in OCD, PTSD, substance use and cost-of-care analyses. So read the counts as database coverage, not as a clean tally of suicidality-specific research, and note that some landmark single-infusion ketamine trials are not in our set, so the picture below is conservative rather than complete. The large majority of the records we do track involve ketamine or esketamine rather than classic psychedelics, which itself tells you where the real evidence sits.

What suicidality is, and why speed matters

Suicidality runs from fleeting thoughts that life is not worth living to active ideation, plans, attempts and death. The WHO estimates more than 727,000 suicide deaths a year worldwide[1]WHO suicide fact sheet (2025). It is rarely a condition in isolation; it travels with depression, bipolar disorder, PTSD, substance use and acute crises. The treatments with the best evidence for actually lowering suicide risk are not new and not psychedelic: psychotherapies such as CBT for suicide prevention and dialectical behaviour therapy, lithium in mood disorders, clozapine in schizophrenia, restricting access to lethal means, and timely human support.

What those tools lack is speed. Standard antidepressants take weeks, and in young people carry a warning about a possible early increase in suicidal thinking. That delay is most dangerous exactly when risk peaks. The entire rationale for ketamine-class drugs in this setting is that they can lower suicidal ideation within hours, potentially bridging the dangerous gap until slower treatments and support take effect. Holding that promise and its limits in view at the same time is the work of this page.

Ketamine: fast, real, and short-lived

Intravenous racemic ketamine has the most convincing rapid-acting signal for suicidal ideation. A midazolam-controlled trial in treatment-resistant depression with prominent suicidal ideation[2]Int. J. Neuropsychopharmacology, midazolam-controlled ketamine RCT (2023) and real-world infusion data[3]Psychiatry Research, real-world IV ketamine (2024) both show suicidal thoughts dropping within hours to days. Because no company owns the molecule, it is cheap and widely used off-label, but for the same reason access, dosing and quality are inconsistent across clinics.

The weakness is durability. The benefit fades within days to weeks, so a dramatic acute response becomes an open-ended maintenance question. Research is testing how to extend it, for instance adding low-dose buprenorphine after an infusion produced greater reduction in suicidal ideation than placebo, with no change in depression scores[4]Am. J. Psychiatry, buprenorphine-after-ketamine RCT (2026), a hint that the antisuicidal and antidepressant effects may be partly separable. But ketamine is a controlled drug with genuine abuse potential, illustrated by a case of addiction after a single infusion given for acute suicidality[5]BJPsych Open, case report (2026), and its evidence in acutely suicidal adolescents is weak, with a paediatric ED pilot showing no significant ideation benefit over control[6]BMC Psychiatry, paediatric ED ketamine pilot (2026).

Esketamine: an approval that names suicidality, with an asterisk

Esketamine (Spravato) is the only compound here whose label names suicidality. In 2020 the FDA approved it for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behaviour[7]FDA approval of Spravato for MDD with acute suicidal ideation or behaviour (2020), on the back of the ASPIRE I and ASPIRE II trials[8]Quality of Life Research, ASPIRE I/II pooled analysis (2023), which showed rapid improvement in depression within 24 hours added to comprehensive standard care. For a field starved of regulatory validation, that mattered.

The asterisk is large and comes straight from the regulator: the label states that effectiveness in preventing suicide, or in reducing suicidal ideation or behaviour, has not been demonstrated. The trial data agree. A 2025 PRISMA meta-analysis found the suicidality effect was not significant at any time point, while the depression effect was modest (effect size roughly 0.15 to 0.23)[9]Am. J. Psychiatry, PRISMA meta-analysis (2025); a 2026 relapse-prevention trial found no group difference on the Columbia Suicide Severity Rating Scale[10]J. Clinical Psychiatry, CBT-ENDURE RCT (2026); and in adolescents esketamine improved depression but not suicidality severity specifically[11]J. Am. Acad. Child Adolesc. Psychiatry (2026). The pattern is consistent: depression improves, the suicidality-specific needle does not reliably move against control.

Classic psychedelics: promising elsewhere, not here

The classic psychedelics, where most of the public excitement lives, are the weakest part of the suicidality evidence. For psilocybin, the most direct study is a 2026 open-label trial of a single dose for chronic suicidal ideation (n=20) reporting large, sustained within-group reductions and no serious adverse events[12]J. Clinical Psychiatry, open-label psilocybin for chronic SI (2026), but with no control group and only twenty participants it is hypothesis-generating, and the authors say so. Set against it is a safety signal: in a 2026 treatment-resistant depression RCT, psilocybin missed its primary endpoint and was associated with more suicidal ideation on dosing days[13]JAMA Psychiatry, EPISODE RCT (2026).

A broader review found serious adverse events, including suicidal behaviour, worsening depression and psychosis, in around 4% of participants with pre-existing neuropsychiatric disorders[14]JAMA Psychiatry, adverse-events meta-analysis (2024). Ayahuasca is weaker still, limited to small qualitative reports[15]Exploratory qualitative study (2026) with no controlled evidence, and it carries real interaction and destabilisation risks in unsupervised settings. Population surveys sometimes report associations between psychedelic use and lower impulsivity or distress, for example a naturalistic survey of 2,510 people[16]Preventive Medicine Reports, naturalistic survey (2025), but these are cross-sectional, self-reported and heavily confounded, and cannot establish that psychedelics reduce suicide. Crucially, most of these trials exclude people at acute suicide risk, so they say little about the population this page concerns.

The gap between reducing ideation and preventing suicide

This is the single most important idea on the page. A drug can lower a suicidal-ideation score in a trial without having been shown to save lives, because suicide is rare enough that no trial so far has been large or long enough to measure deaths, because rated ideation and actual behaviour are not the same thing, and because effects that fade within weeks may not cover the period of risk. That is why the esketamine label is careful, and why every claim here separates "reduced suicidal thinking in a study" from "prevents suicide". Treat any source that blurs the two with suspicion.

Safety, and who is left out

The safety picture is genuinely mixed and should be presented as such. Post-marketing analyses of esketamine disagree: a European pharmacovigilance analysis flagged a potential increase in suicide risk versus older antidepressants[17]Pharmaceuticals, EudraVigilance analysis (2025), while a near-five-year US real-world analysis found no new safety signals[18]Am. J. Psychiatry, real-world esketamine safety (2025). Ketamine carries abuse potential; classic psychedelics can worsen ideation acutely in vulnerable people. And running through all of it is a selection problem: the people at highest risk, those who are actively suicidal, are routinely excluded from the trials, so the evidence is strongest for exactly the people who need it least and thinnest for those who need it most.

Reading this honestly

So where does suicidality sit? It is a setting where rapid-acting drugs can do something real and fast, lower suicidal thoughts within hours, which is not nothing when the alternative is weeks of waiting. But the honest reading refuses two temptations: the breathless one that treats a fast drop in ideation as a cure for suicide, and the dismissive one that ignores a genuine, regulator-recognised tool. The defensible position is narrow and cautious: ketamine and esketamine can help reduce acute suicidal ideation under medical supervision, suicide prevention itself remains unproven for every compound here, classic psychedelics are not a treatment for suicidality and may be hazardous in crisis, and none of this substitutes for human support, safety planning and timely professional care. If you are struggling, please use the crisis resources at the top of this report.